Top Markets
#1 Black Phoenix Black Phoenix +356.03%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +56.21%
#4 Akedo Akedo +46.51%
#5 Acurast Acurast +34.08%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.76%
#7 BasedHype BasedHype +25.78%
#8 Avantis Avantis +21.64%
#9 Cryptopia Cryptopia +21.54%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +16.54%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Clarus Therapeutics Holdings, Inc. Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc.

CRXTQ
Classifica tra le azioni #40849
Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to... Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to developing and marketing oral testosterone replacement therapies across the United States. Its primary offering is JATENZO, an oral soft gel formulation of testosterone undecanoate, prescribed for men suffering from hypogonadism. The company has also entered into licensing agreements, including one with HavaH Therapeutics for androgen treatments targeting inflammatory breast disease and specific types of breast cancer. Additionally, Clarus holds an agreement with The Royal Institution for the Advancement of Learning/McGill University to advance and commercialize McGill's exclusive technology, which is designed to address human conditions associated with CoQ10 deficiencies. Founded in 2003, Clarus Therapeutics Holdings, Inc. is headquartered in Northbrook, Illinois. On September 5, 2022, the company, along with an affiliate, voluntarily sought reorganization under Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.
Prezzo delle azioni
$0.0014
Ultima sincronizzazione: 2023-02-28
Capitalizzazione di mercato
$72.83K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Clarus Therapeutics Holdings, Inc. (CRXTQ)

Categoria

Healthcare
Ricavi di Clarus Therapeutics Holdings, Inc. (CRXTQ)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Clarus Therapeutics Holdings, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Clarus Therapeutics Holdings, Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 $79.67B -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 $97.93B -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 $64.39B -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 $77.52B -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 $66.40B -
US